Troy Edward Wilson
Known title: DirectorCIK: 0001589597
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project. Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.
Transaction History
| PBYI | ▼ Sell | Open Market | 5,000 | $46K | 9/14/2026 | View on chart |
| PBYI | ▼ Sell | Open Market | 10,800 | $78K | 6/12/2026 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/11/2026 | View on chart |
| KURA | ▲ Buy | Option Exercise | 6,103 | $38K | 3/23/2026 | View on chart |
| KURA | ▲ Buy | Grant | 182,500 | $0 | 11/13/2025 | View on chart |
| KURA | ▼ Sell | Open Market | 36,615 | $327K | 9/29/2025 | View on chart |
| KURA | ▲ Buy | Grant | 182,500 | $0 | 9/27/2025 | View on chart |
| PBYI | ▼ Sell | Open Market | 10,800 | $37K | 6/13/2025 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/11/2025 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/18/2024 | View on chart |
| PBYI | ▼ Sell | Open Market | 27,000 | $90K | 6/13/2024 | View on chart |
| PBYI | ▼ Sell | Open Market | 27,000 | $93K | 6/13/2023 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/13/2023 | View on chart |
| PBYI | ▼ Sell | Open Market | 27,858 | $72K | 6/16/2022 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Puma Biotechnology inducement award under Nasdaq Rule 5635(c)(4)
Puma Biotechnology disclosed that it received an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4). The award is intended to assist the company in meeting Nasdaq's continued listing requirements. This filing is a regulatory update that informs investors of the company's compliance actions.
Puma Biotechnology inducement award under Nasdaq Rule 5635(c)(4). Puma Biotechnology disclosed that it received an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4). The award is intended to assist the company in meeting Nasdaq's continued listing requirements. This filing is a regulatory update that informs investors of the company's compliance actions.